-
公开(公告)号：US20150366994A1
公开(公告)日：2015-12-24
申请号：US14790561
申请日：2015-07-02
CPC分类号： A61K38/19 , A61K9/127 , A61K9/5153 , A61K47/6849 , A61K47/6913 , A61K47/6925 , B82Y5/00
摘要： A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease.
摘要翻译： 用于调节哺乳动物中免疫应答的组合物，其包含药学上可接受的载体溶液和多种可生物降解的纳米颗粒，其中所述纳米颗粒包含能够选择性地结合T淋巴细胞和/或血管的表面的靶向部分 内皮细胞，并且其中所述纳米颗粒进一步包含白血病抑制因子（LIF）。 纳米粒子介导的LIF的靶向递送可用于指导患者的耐受性发生，并且对于器官移植物的接受者以及患有自身免疫性疾病的患者具有即时临床应用。
-
公开(公告)号：US09101548B2
公开(公告)日：2015-08-11
申请号：US12739357
申请日：2008-10-24
CPC分类号： A61K47/48869 , A61K9/127 , A61K9/5153 , A61K38/19 , A61K47/6849 , A61K47/6913 , A61K47/6925 , B82Y5/00
摘要： A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease.
摘要翻译： 用于调节哺乳动物中免疫应答的组合物，其包含药学上可接受的载体溶液和多种可生物降解的纳米颗粒，其中所述纳米颗粒包含能够选择性地结合T淋巴细胞和/或血管的表面的靶向部分 内皮细胞，并且其中所述纳米颗粒进一步包含白血病抑制因子（LIF）。 纳米粒子介导的LIF的靶向递送可用于指导患者的耐受性发生，并且对于器官移植物的接受者以及患有自身免疫性疾病的患者具有即时临床应用。
-
公开(公告)号：US20150231266A1
公开(公告)日：2015-08-20
申请号：US14628050
申请日：2015-02-20
发明人： Susan Marie Metcalfe , Tarek Fahmy
CPC分类号： A61K47/42 , A61K9/4866 , A61K38/1808 , A61K38/185 , A61K38/204 , A61K38/2093 , A61K47/6907 , B82Y5/00 , C07K16/2863 , A61K2300/00
摘要： There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of : brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.
摘要翻译： 提供治疗神经变性疾病和CNS损伤的组合物和方法。 所述组合物是药学上可接受的载体溶液; 和多个可生物降解的纳米颗粒，其中所述纳米颗粒包含能够选择性地结合神经干细胞表面的靶向部分，并且其中所述纳米颗粒进一步包含诸如白血病抑制因子（LIF）等因素。 XAV939和/或一种或多种：脑源性神经营养因子（BDNF）或其激动剂; 表皮生长因子（EGF）或其激动剂; 神经胶质细胞衍生的神经营养因子（GDNF）或其激动剂; 视黄酸及其衍生物; 睫状神经营养因子（CTNF）或其激动剂; 和Wnt5A。 可生物降解的纳米颗粒可以通过受控的时间释放递送。
-
公开(公告)号：US20180271985A1
公开(公告)日：2018-09-27
申请号：US15990259
申请日：2018-05-25
发明人： Susan Marie Metcalfe , Tarek Fahmy
CPC分类号： A61K47/42 , A61K9/4866 , A61K38/1808 , A61K38/185 , A61K38/204 , A61K38/2093 , A61K47/6907 , B82Y5/00 , C07K16/2863 , A61K2300/00
摘要： There are provided compositions and methods for treatment of neurodegeneative diseases and CNS injury. The compositions a pharmaceutically acceptable carrier solution; and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a neural stem cell and wherein the nanoparticles further comprise factors such as leukaemia inhibitory factor (LIF); XAV939 and/or one or more of: brain-derived neurotrophic factor (BDNF) or an agonist thereof; epidermal growth factor (EGF) or an agonist thereof; glial cell-derived neurotrophic factor (GDNF) or an agonist thereof; retinoic acid and derivatives thereof; ciliary neurotrophic factor (CTNF) or an agonist thereof; and Wnt5A. The biodegradable nanoparticles may deliver via controlled time release.
-
公开(公告)号：US20080125390A1
公开(公告)日：2008-05-29
申请号：US11873586
申请日：2007-10-17
CPC分类号： A61K39/39 , A61K38/53 , A61K2039/55516 , Y10T436/143333
摘要： A method for controlling leukaemia inhibitory factor (LIF)-interferon gamma inflammatory axis is provided. Control of interferon gamma production or release is mediated via modulation of the expression or activity of axotrophin (MARCH VII). Methods are provided for treating an animal that has received allografted tissue as well as for treating an animal that is immuno-compromised.
摘要翻译： 提供了一种控制白血病抑制因子（LIF） - 干扰素γ炎症轴的方法。 干扰素γ产生或释放的控制通过调节轴突营养素（MARCH VII）的表达或活性来介导。 提供了用于治疗已经接受同种异体移植组织的动物以及用于治疗免疫缺陷的动物的方法。
-
公开(公告)号：US20100310639A1
公开(公告)日：2010-12-09
申请号：US12739357
申请日：2008-10-24
申请人： Susan Marie Metcalfe
发明人： Susan Marie Metcalfe
IPC分类号： A61K9/127 , A61K9/16 , A61K39/395 , A61K39/00 , C12N5/02
CPC分类号： A61K47/48869 , A61K9/127 , A61K9/5153 , A61K38/19 , A61K47/6849 , A61K47/6913 , A61K47/6925 , B82Y5/00
摘要： A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease.
摘要翻译： 用于调节哺乳动物中免疫应答的组合物，其包含药学上可接受的载体溶液和多种可生物降解的纳米颗粒，其中所述纳米颗粒包含能够选择性地结合T淋巴细胞和/或血管的表面的靶向部分 内皮细胞，并且其中所述纳米颗粒进一步包含白血病抑制因子（LIF）。 纳米粒子介导的LIF的靶向递送可用于指导患者的耐受性发生，并且对于器官移植物的接受者以及患有自身免疫性疾病的患者具有即时临床应用。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.014 秒)
